{"id":66331,"date":"2026-05-26T14:35:24","date_gmt":"2026-05-26T06:35:24","guid":{"rendered":"https:\/\/flcube.com\/?p=66331"},"modified":"2026-05-26T14:35:25","modified_gmt":"2026-05-26T06:35:25","slug":"china-medical-system-secures-nmpa-approval-for-cms-d001-tyk2-inhibitor-in-ulcerative-colitis-and-crohns-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66331","title":{"rendered":"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn&#8217;s Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China Medical System Holdings Limited<\/strong> (CMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>) announced it has received <strong>clinical trial authorization from China&#8217;s National Medical Products Administration (NMPA)<\/strong> to initiate a clinical study of <strong>CMS-D001<\/strong>, a <strong>highly selective tyrosine kinase 2 (TYK2) inhibitor<\/strong>, for the treatment of <strong>ulcerative colitis (UC)<\/strong> and <strong>Crohn&#8217;s disease (CD)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CMS-D001 \u2013 highly selective TYK2 inhibitor<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Ulcerative colitis (UC) and Crohn&#8217;s disease (CD)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>May 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Patient enrollment and Phase I\/II clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Highly selective tyrosine kinase 2 (TYK2) inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Target Specificity:<\/strong> Specifically inhibits <strong>TYK2 activation<\/strong> while minimizing impact on other JAK family kinases (JAK1, JAK2, JAK3)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks cellular signaling pathways of key inflammatory cytokines:<\/li>\n\n\n\n<li><strong>IL-23<\/strong> \u2013 critical driver of chronic inflammation in IBD<\/li>\n\n\n\n<li><strong>IL-12<\/strong> \u2013 promotes Th1 immune responses in Crohn&#8217;s disease<\/li>\n\n\n\n<li><strong>Type I interferons<\/strong> \u2013 involved in autoimmune pathogenesis<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Suppresses pathological autoimmune processes while maintaining broader immune function<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> Reduced off-target effects on other JAK kinases potentially translate to improved safety profile compared to pan-JAK inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-differentiation-in-ibd-market\" class=\"wp-block-heading\">Competitive Differentiation in IBD Market<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>CMS-D001 (TYK2 Selective)<\/th><th>Pan-JAK Inhibitors<\/th><th>Anti-TNF Biologics<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Specificity<\/strong><\/td><td><strong>Highly selective for TYK2<\/strong><\/td><td>Broad JAK family inhibition<\/td><td>TNF-alpha specific<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Oral small molecule<\/td><td>Oral small molecule<\/td><td>Subcutaneous\/IV biologic<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td><strong>Potentially improved<\/strong> (reduced hematologic\/toxic effects)<\/td><td>Higher risk of adverse events<\/td><td>Injection-related reactions, immunogenicity<\/td><\/tr><tr><td><strong>Cost<\/strong><\/td><td>Lower (small molecule)<\/td><td>Lower (small molecule)<\/td><td>Higher (biologic)<\/td><\/tr><tr><td><strong>Market Stage<\/strong><\/td><td>Early clinical development<\/td><td>Established (Xeljanz, Rinvoq)<\/td><td>Well-established (Humira, Remicade)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-positioning\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>IBD Prevalence in China<\/strong><\/td><td>Estimated 1.5-2 million UC\/CD patients, growing at 8-10% annually<\/td><\/tr><tr><td><strong>Current Treatment Gap<\/strong><\/td><td>Limited oral options with favorable safety profiles; high unmet need for effective, convenient therapies<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Dominated by biologics (anti-TNF, anti-integrins); emerging JAK inhibitors face safety concerns<\/td><\/tr><tr><td><strong>CMS Strategic Advantage<\/strong><\/td><td>First-mover potential in selective TYK2 inhibition for IBD in China; leverages CMS&#8217;s strong commercial infrastructure<\/td><\/tr><tr><td><strong>Global Context<\/strong><\/td><td>Follows success of BMS&#8217;s deucravacitinib (Sotyktu) in psoriasis; validates TYK2 as therapeutic target<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The selective TYK2 inhibition approach represents a next-generation strategy in inflammatory bowel disease treatment, potentially offering the convenience of oral administration with an improved safety profile compared to existing JAK inhibitors.<\/p>\n\n\n\n<h2 id=\"h-development-strategy-amp-commercial-outlook\" class=\"wp-block-heading\">Development Strategy &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Pathway:<\/strong> Initial focus on Chinese patient population with potential global expansion<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Category 1 innovative drug designation possible, enabling expedited review and premium pricing<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> CMS&#8217;s established hospital sales force provides immediate market access across China&#8217;s tier 1-3 cities<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Strong candidate for international licensing given validated TYK2 target and differentiated profile<\/li>\n\n\n\n<li><strong>Timeline Expectations:<\/strong> Phase I\/II data expected 2027-2028; potential NDA submission 2029 if successful<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for CMS-D001. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052600024_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052600024_c.\"><\/object><a id=\"wp-block-file--media-36c9ad31-af5b-4053-9199-076742798e8f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052600024_c.pdf\">2026052600024_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052600024_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-36c9ad31-af5b-4053-9199-076742798e8f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,325,62,844],"class_list":["post-66331","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-china-medical-system","tag-clinical-trial-approval-initiation","tag-hkg-0867"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn&#039;s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study of CMS-D001, a highly selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of ulcerative colitis (UC) and Crohn&#039;s disease (CD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66331\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn&#039;s Disease\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study of CMS-D001, a highly selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of ulcerative colitis (UC) and Crohn&#039;s disease (CD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66331\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T06:35:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-26T06:35:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66331#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66331\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn&#8217;s Disease\",\"datePublished\":\"2026-05-26T06:35:24+00:00\",\"dateModified\":\"2026-05-26T06:35:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66331\"},\"wordCount\":503,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"China Medical System\",\"Clinical trial approval \\\/ initiation\",\"HKG: 0867\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66331#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66331\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66331\",\"name\":\"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-26T06:35:24+00:00\",\"dateModified\":\"2026-05-26T06:35:25+00:00\",\"description\":\"China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization from China's National Medical Products Administration (NMPA) to initiate a clinical study of CMS-D001, a highly selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66331#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66331\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66331#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn&#8217;s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry","description":"China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization from China's National Medical Products Administration (NMPA) to initiate a clinical study of CMS-D001, a highly selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66331","og_locale":"en_US","og_type":"article","og_title":"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn's Disease","og_description":"China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization from China's National Medical Products Administration (NMPA) to initiate a clinical study of CMS-D001, a highly selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).","og_url":"https:\/\/flcube.com\/?p=66331","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-26T06:35:24+00:00","article_modified_time":"2026-05-26T06:35:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66331#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66331"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn&#8217;s Disease","datePublished":"2026-05-26T06:35:24+00:00","dateModified":"2026-05-26T06:35:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66331"},"wordCount":503,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","China Medical System","Clinical trial approval \/ initiation","HKG: 0867"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66331#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66331","url":"https:\/\/flcube.com\/?p=66331","name":"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-26T06:35:24+00:00","dateModified":"2026-05-26T06:35:25+00:00","description":"China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization from China's National Medical Products Administration (NMPA) to initiate a clinical study of CMS-D001, a highly selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66331#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66331"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66331#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn&#8217;s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66331"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66331\/revisions"}],"predecessor-version":[{"id":66333,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66331\/revisions\/66333"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}